Industry News
Biotechnology Industry News

Sarepta, with pivotal data in sight, dumps Lysogene gene therapy
Sarepta, with pivotal data in sight, dumps Lysogene gene therapy ntaylor Thu, 01/13/2022 - 08:27
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker chale Thu, 01/13/2022 - 08:25
JPM22, Day 4: Galapagos plots rebound with M&A, new CEO; Gritstone hopes for new cancer biomarker; Vertex’s cystic fibrosis dominance
JPM22, Day 4: Galapagos plots rebound with M&A, new CEO; Gritstone hopes for new cancer biomarker; Vertex's cystic fibrosis dominance chale Thu, 01/13/2022 - 08:25
AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targets
AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targets ntaylor Thu, 01/13/2022 - 07:48
JPM22, Day 3: BeiGene, Ionis promise ‘tidal wave’ of new drugs; Roche launches smart, point-of-care glucose monitor
JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor aarmstrong Wed, 01/12/2022 - 08:27
JPM22, Day 3: Intellia, Editas plan to double down on gene editing data in 2022; Roche launches smart glucose monitor
JPM22, Day 3: Intellia, Editas plan to double down on gene editing data in 2022; Roche launches smart glucose monitor aarmstrong Wed, 01/12/2022 - 08:27
Sanofi makes $75M preclinical bet to join Roche, Novartis and more in congested Parkinson’s field
Sanofi makes $75M preclinical bet to join Roche, Novartis and more in congested Parkinson's field ntaylor Wed, 01/12/2022 - 08:16
Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development
Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development ntaylor Wed, 01/12/2022 - 06:09
Sana links arms with IASO, Innovent in $204M biobucks pact to use CAR construct in up to 6 cell and gene therapies
Sana links arms with IASO, Innovent in $204M biobucks pact to use CAR construct in up to 6 cell and gene therapies klahucik Tue, 01/11/2022 - 12:26
Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 IND
Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 IND ntaylor Tue, 01/11/2022 - 08:14
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis badams Tue, 01/11/2022 - 04:50
JPM22, Day 2: Sage’s double-duty anxiety drug; Dexcom shows off G7 sensor data; Better late than never for Enanta in COVID
JPM22, Day 2: Sage's double-duty anxiety drug; Dexcom shows off G7 sensor data; Better late than never for Enanta in COVID badams Tue, 01/11/2022 - 04:50
JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15%
JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15% klahucik Mon, 01/10/2022 - 11:50
Amgen dons BigHat to bring AI insights to next-gen antibodies
Amgen dons BigHat to bring AI insights to next-gen antibodies ntaylor Mon, 01/10/2022 - 11:04
JPM 2022: Moderna finds Carisma’s macrophage tech compelling enough for $45M cancer research deal
JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal aarmstrong Mon, 01/10/2022 - 09:33
JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed Century, $70M upfront to ArsenalBio
JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed Century, $70M upfront to ArsenalBio klahucik Mon, 01/10/2022 - 08:19
BioMarin’s hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts ntaylor Mon, 01/10/2022 - 06:59
Maze Therapeutics navigates $190M financing round as it plots course to the clinic
Maze Therapeutics navigates $190M financing round as it plots course to the clinic fkansteiner Mon, 01/10/2022 - 05:55
Novartis splashes cash on COVID-19 antiviral, plans FDA filing as Molecular Partners links drug to drop in hospitalization, death
Novartis splashes cash on COVID-19 antiviral, plans FDA filing as Molecular Partners links drug to drop in hospitalization, death ntaylor Mon, 01/10/2022 - 04:50
JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more
JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more badams Mon, 01/10/2022 - 04:25

